Get quick answers to some of the most common questions on GLP-1 therapies. Get quick answers to some of the most common questions on GLP-1 therapies. Explore how these treatments fit into managed care pharmacy and the nuances of managing this class.
On Sept. 13, 2024, the Internal Revenue Service (IRS), Employee Benefits Security Administration (EBSA), and Centers for Medicare & Medicaid Services (CMS) (collectively, the Departments) released a Final Rule on Requirements Related to the Mental Health Parity and Addiction Equity Act (Final Rule). The Final Rule will be published in the Federal Register on Sept. 23, 2024. Access the Regulatory NewsBREAK to learn more.
On Sept. 13, 2024, the Centers for Medicare & Medicaid Services (CMS) issued a memorandum on Reporting Routing Values for the Medicare Prescription Payment Plan (M3P). Access the Regulatory NewsBREAK to learn more.
On September 9, AMCP submitted comments praising CMS’s proposal to cover Digital Mental Health Treatment devices (DMHTs) under Medicare Part B. AMCP urges CMS to use its authority to cover all FDA-cleared, prescription only digital health products and develop appropriate coding and payment methodologies to promote adoption of these innovative technologies.
SB 966, California's PBM reform bill, could reshape pharmacy benefit manager regulation if signed into law. Governor Newsom’s decision is expected by September 30.
AMCP Comments on Medicare CY 2025. Physician Fee Schedule
On July 31, CMS unveiled a proposed rule covering the CY 2025 Physician Fee Schedule, changes to Part B payment and coverage policies, and the Medicare Prescription Drug Inflation Rebate program, among other policies.
AMCP Names Mitzi Wasik Executive Director, AMCP Foundation and SVP, Practice Strategy and Innovation
AMCP announced the appointment of Mitzi Wasik, PharmD, MBA, BCPS, FAMCP, FCCP, as Executive Director, AMCP Foundation and SVP, Practice Strategy and Innovation, effective September 30.
Welcome to the first Professional Affairs blog! We plan on sharing a periodic post to recap some of the major news, journal articles, reports, and other publications from around the web that have come out since our last post. As this is our first blog, we’ll try to adequately cover the whirlwind that was July and early August 2024.
AMCP CEO Susan Cantrell stresses how collaboration is key in addressing challenges such as high drug prices and healthcare disparities. While there’s no silver bullet, solutions such as tailored population benefit design and value-based contracting can play an important role in making a difference for ordinary Americans looking for affordable access to prescriptions.
Hernandez co-authored a June study in the Journal of Managed Care & Specialty Pharmacy (JMCP) on price benchmarks for selected drugs and their therapeutic alternatives, which concluded different negotiation scenarios for the first 10 drugs. If a drug has a therapeutic alternative, that likely guided the initial price offer from the CMS.
